Ranbaxy fourth quarter loss narrows on U.S. acne drug sales

MUMBAI (Reuters) - Ranbaxy Laboratories, India's biggest generic drugmaker by revenue, reported a narrower net loss in the latest quarter helped by ramped-up sales of two acne drugs in the United States.

Ranbaxy, majority owned by Japan's Daiichi Sankyo Co<4568.T>, on Wednesday said net loss in October-December was 1.59 billion rupees compared with a loss of 4.92 billion rupees a year earlier.

Net sales rose 7 percent to 28.59 billion rupees, the company said in a statement.

The United States, Ranbaxy's biggest export market, has recently banned the import of drugs from the company's India plants due to quality concerns.

(Reporting by Sumeet Chatterjee; Editing by Christopher Cushing)